TractaViewer

TractaViewer assesses therapeutic target druggability by integrating public database evidence to characterize and rank targets for small-molecule ligandability, large-molecule suitability (antibodies), and novel modalities such as antisense oligonucleotides, siRNA, and PROTACs.

Key Features:

• Data Integration: Aggregates and harmonizes evidence from publicly available databases and datasets.
• Target Characterization: Evaluates small-molecule ligandability, antibody suitability, and compatibility with antisense oligonucleotides, siRNA, and PROTAC modalities.
• Target Ranking: Ranks and prioritizes targets based on aggregated tractability evidence.
• Feasibility Assessment: Assesses feasibility by considering availability of assays and existing biological knowledge.
• Safety Evaluation: Identifies potential safety risks using tissue-wise expression and deleterious phenotype data.
• Visualization: Produces visualizations to help interpret complex tractability-related data components.

Scientific Applications:

• Therapeutic hypothesis generation: Summarizes tractability evidence to generate and refine hypotheses for therapeutic targets.
• Target prioritization for development: Prioritizes targets for preclinical and clinical progression based on druggability and feasibility metrics.
• Modality selection: Informs selection among small molecules, antibodies, antisense oligonucleotides, siRNA, and PROTACs according to target characteristics.

Methodology:

Integrates and aggregates publicly available database datasets, evaluates ligandability and modality suitability, assesses feasibility using assay availability and biological knowledge, assesses safety via tissue-wise expression and phenotype data, and provides visualization of tractability components.